Feasibility, safety, and efficacy of robotic single-port hysterectomy (R-SPH) using the da Vinci SP system in low-risk endometrial cancer: a pilot study.

IF 2 4区医学 Q2 SURGERY

Minimally Invasive Therapy & Allied Technologies Pub Date : 2025-08-11 DOI:10.1080/13645706.2025.2538764

Riccardo Vizza, Giacomo Corrado, Emanuela Mancini, Ermelinda Baiocco, Mario Russo, Cristina Vincenzoni, Valentina Bruno, Henrik Falconer, Enrico Vizza

{"title":"Feasibility, safety, and efficacy of robotic single-port hysterectomy (R-SPH) using the da Vinci SP system in low-risk endometrial cancer: a pilot study.","authors":"Riccardo Vizza, Giacomo Corrado, Emanuela Mancini, Ermelinda Baiocco, Mario Russo, Cristina Vincenzoni, Valentina Bruno, Henrik Falconer, Enrico Vizza","doi":"10.1080/13645706.2025.2538764","DOIUrl":null,"url":null,"abstract":"Background: The purpose of this study was to evaluate the feasibility, safety, and efficacy of robotic single-port hysterectomy (R-SPH) with the da Vinci SP in low-risk endometrial cancer.Methods: Patients with clinically confirmed endometrioid endometrial cancer, FIGO stages IA-IB, were enrolled for R-SPH. All surgical procedures were performed through a single 2.5 cm umbilical incision. An Intuitive Access Port of small size was placed into the incision, and pneumoperitoneum was established. Robotic instruments were inserted as described below through the Intuitive Access Port, which has four different channel ports: in the superior channel, a three-dimensional 8.5 mm optics; in channel 1, Cadiere Forceps; in channel 2, a Maryland Bipolar; and in channel 3, monopolar scissors.Results: From June 24 to November 13, 2024, a total of 25 patients were included in the study. The median age was 61 years, and median BMI was 25.9 kg/m2. The median docking time, console time, and total operative time were 10, 65, and 115 min, respectively. The median blood loss was 67.0 mL, and the median hemoglobin drop was 1.2 g/dL.Conclusions: R-SPH seems safe and feasible in endometrial cancer. The true benefit of the technique should be sought in larger comparative studies. ClinicalTrials.gov Protocol Record: NCT06681831.","PeriodicalId":18537,"journal":{"name":"Minimally Invasive Therapy & Allied Technologies","volume":" ","pages":"1-8"},"PeriodicalIF":2.0000,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Minimally Invasive Therapy & Allied Technologies","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13645706.2025.2538764","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The purpose of this study was to evaluate the feasibility, safety, and efficacy of robotic single-port hysterectomy (R-SPH) with the da Vinci SP in low-risk endometrial cancer.

Methods: Patients with clinically confirmed endometrioid endometrial cancer, FIGO stages IA-IB, were enrolled for R-SPH. All surgical procedures were performed through a single 2.5 cm umbilical incision. An Intuitive Access Port of small size was placed into the incision, and pneumoperitoneum was established. Robotic instruments were inserted as described below through the Intuitive Access Port, which has four different channel ports: in the superior channel, a three-dimensional 8.5 mm optics; in channel 1, Cadiere Forceps; in channel 2, a Maryland Bipolar; and in channel 3, monopolar scissors.

Results: From June 24 to November 13, 2024, a total of 25 patients were included in the study. The median age was 61 years, and median BMI was 25.9 kg/m². The median docking time, console time, and total operative time were 10, 65, and 115 min, respectively. The median blood loss was 67.0 mL, and the median hemoglobin drop was 1.2 g/dL.

Conclusions: R-SPH seems safe and feasible in endometrial cancer. The true benefit of the technique should be sought in larger comparative studies. ClinicalTrials.gov Protocol Record: NCT06681831.

查看原文本刊更多论文

使用达芬奇SP系统进行机器人单孔子宫切除术（R-SPH）治疗低风险子宫内膜癌的可行性、安全性和有效性：一项试点研究。

背景：本研究的目的是评估机器人单孔子宫切除术（R-SPH）与达芬奇SP治疗低危子宫内膜癌的可行性、安全性和有效性。方法：临床确诊的子宫内膜样子宫内膜癌FIGO分期IA-IB期患者进行R-SPH治疗。所有手术均通过单个2.5 cm脐切口进行。在切口内放置小尺寸的直观访问口，建立气腹。机器人仪器通过直观访问端口插入，如下所述，该端口有四个不同的通道端口：在高级通道中，三维8.5毫米光学器件；通道1，卡迪埃钳；第二频道是马里兰州的躁郁症患者；通道3是单极子剪刀。结果：2024年6月24日至11月13日，共纳入25例患者。中位年龄为61岁，中位BMI为25.9 kg/m2。中位对接时间、控制台时间和总手术时间分别为10分钟、65分钟和115分钟。中位失血量67.0 mL，中位血红蛋白下降1.2 g/dL。结论：R-SPH治疗子宫内膜癌是安全可行的。这项技术的真正好处应该在更大规模的比较研究中寻找。ClinicalTrials.gov协议记录：NCT06681831。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Minimally Invasive Therapy & Allied Technologies 医学-外科

CiteScore

3.80

自引率

5.90%

发文量

审稿时长

6-12 weeks

期刊介绍： Minimally Invasive Therapy and Allied Technologies (MITAT) is an international forum for endoscopic surgeons, interventional radiologists and industrial instrument manufacturers. It is the official journal of the Society for Medical Innovation and Technology (SMIT) whose membership includes representatives from a broad spectrum of medical specialities, instrument manufacturing and research. The journal brings the latest developments and innovations in minimally invasive therapy to its readers. What makes Minimally Invasive Therapy and Allied Technologies unique is that we publish one or two special issues each year, which are devoted to a specific theme. Key topics covered by the journal include: interventional radiology, endoscopic surgery, imaging technology, manipulators and robotics for surgery and education and training for MIS.